TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02534350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Presatovir
Description: Tablets administered orally or via nasogastric (NG) tube once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets administered orally or via NG tube once daily
Study: NCT04023019

Intervention type: BIOLOGICAL
Intervention: Nuwiq
Description: Nuwiq is a recombinant FVIII concentrate from a human cell line. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.

Intervention type: BIOLOGICAL
Intervention: Octanate
Description: Octanate is a high-purity human Factor VIII / von Willebrand Factor (VWF) concentrate. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
Study: NCT00688168

Intervention type: BEHAVIORAL
Intervention: Neurocognitive Testing
Description: A neurocognitive exam (tests to check your memory and thinking abilities, for example) will be performed.

Intervention type: BEHAVIORAL
Intervention: Neurosensory Testing
Description: Neurosensory testing will be performed to find out how sensitive you are to things such as touch, coolness, warmth, pinprick on the finger, and squeezing of the skin on the finger, hand, or arm.
Study: NCT03383718

Intervention type: PROCEDURE
Intervention: Revascularisation
Description: Percutaneous coronary intervention or coronary artery bypass surgery

Intervention type: OTHER
Intervention: Optimal Medical Treatment/OMT
Description: Standard of care in stable coronary artery disease or after acute myocardial infarction.
Study: NCT00738543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WHOLE GROUP OF 48 VOLUNTEERS
Description: Two antiseptics (10% povidone iodine and 10% sodium hypochlorite) and one control were tested as skin antiseptics. The intervention consisted of preparing the skin with the antiseptic or the control. The areas were approximately 25 cm2 on the forearm for each antiseptic or control. The antiseptic or control were applied in an outward circular motion using a swab that was soaked with the solution. The solution was then kept on the skin for 60 seconds before the bacterial culture was conducted. All volunteers were instructed to continue the use of neutral soap and shampoo without antiseptics during the follow-up period.
Study: NCT03302793

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BreEStim
Description: BreEStim will applied for 10 to 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BreEStim
Description: BreEStim will applied for 10 to 20 minutes.
Study: NCT02578108

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: genicular nerve diagnostic block with lidocaine (local anesthetic)
Description: sensory denervation of the knee joint
Study: NCT04023019

Intervention type: BIOLOGICAL
Intervention: Octanate
Description: Octanate is a high-purity human Factor VIII / von Willebrand Factor (VWF) concentrate. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.

Intervention type: BIOLOGICAL
Intervention: Wilate
Description: Wilate is a high-purity human von Willebrand Factor (VWF)/Factor VIII concentrate. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.

Intervention type: BIOLOGICAL
Intervention: Wilate
Description: Wilate is a high-purity human von Willebrand Factor (VWF)/Factor VIII concentrate. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.

Intervention type: BIOLOGICAL
Intervention: Emicizumab
Description: Emicizumab is a therapeutic antibody which brings activated factor IX and factor X together It is administered via subcutaneous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
Study: NCT02488031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biomechanical Assessments of Dysmetria
Description: Dysmetria will be assessed using a custom-made goal-directed movement protocol where participant perform unloaded limb movement tasks and attempt to reach a space-time target. During these task muscle activity is monitored using Electromyography (EMG) recording.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biomechanical Assessments of Dysmetria
Description: Dysmetria will be assessed using a custom-made goal-directed movement protocol where participant perform unloaded limb movement tasks and attempt to reach a space-time target. During these task muscle activity is monitored using Electromyography (EMG) recording.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurophysiological assessment of brain activity
Description: Neurophysiology will be assessed by monitoring brain activity using Task-based fMRI and motor unit pool activity using a specialized EMG system.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurophysiological assessment of brain activity
Description: Neurophysiology will be assessed by monitoring brain activity using Task-based fMRI and motor unit pool activity using a specialized EMG system.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biomechanical gait analysis
Description: Participants will wear APDM's wireless sensors on the hands, legs, trunk and forehead and walk overground a distance of 7 m for 2 minutes. APDM quantifies 80 common biomechanical outcomes of gait (e.g. stride length variability).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biomechanical gait analysis
Description: Participants will wear APDM's wireless sensors on the hands, legs, trunk and forehead and walk overground a distance of 7 m for 2 minutes. APDM quantifies 80 common biomechanical outcomes of gait (e.g. stride length variability).
Study: NCT04023019

Intervention type: BIOLOGICAL
Intervention: Emicizumab
Description: Emicizumab is a therapeutic antibody which brings activated factor IX and factor X together It is administered via subcutaneous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.

Intervention type: BIOLOGICAL
Intervention: Recombinant factor VIIa (rFVIIa)
Description: Recombinant factor VIIa (rFVIIa) is a blood factor VII manufactured using recombinant technology. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.

Intervention type: BIOLOGICAL
Intervention: Recombinant factor VIIa (rFVIIa)
Description: Recombinant factor VIIa (rFVIIa) is a blood factor VII manufactured using recombinant technology. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.

Intervention type: BIOLOGICAL
Intervention: Recombinant factor VIIa (rFVIIa)
Description: Recombinant factor VIIa (rFVIIa) is a blood factor VII manufactured using recombinant technology. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.

Intervention type: BIOLOGICAL
Intervention: Activated prothrombin complex concentrate (aPCC)
Description: Activated prothrombin complex concentrate (aPCC) is an anti-inhibitor coagulant complex acting on multiple pathways to facilitate coagulation. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.

Intervention type: BIOLOGICAL
Intervention: Activated prothrombin complex concentrate (aPCC)
Description: Activated prothrombin complex concentrate (aPCC) is an anti-inhibitor coagulant complex acting on multiple pathways to facilitate coagulation. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.

Intervention type: BIOLOGICAL
Intervention: Activated prothrombin complex concentrate (aPCC)
Description: Activated prothrombin complex concentrate (aPCC) is an anti-inhibitor coagulant complex acting on multiple pathways to facilitate coagulation. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
Study: NCT02578108

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: genicular nerve radiofrequency ablation
Description: Ablation of the genicular nerves of the knee by radiofrequency energy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: genicular nerve radiofrequency ablation
Description: Ablation of the genicular nerves of the knee by radiofrequency energy
Study: NCT04094155

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: retinal vascular analysis
Description: Retinal fundoscopy over a 3 week period in stationary patients after aneurysmatic subarachnoid hemorrhage
Study: NCT00549536

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: tablets each containing of 1000mg elemental calcium (Mega-Calcium Sandoz)
Description: 1500 mg of elemental calcium per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: NO_INTERVENTION
Intervention: tablets each containing of 1000mg elemental calcium (Mega-Calcium Sandoz)
Description: 1500 mg of elemental calcium per day.
Study: NCT01184235

Intervention type: DRUG
Intervention: Pharmacological Intervention
Description: This study will include those anticipating or receiving any pharmacological intervention

Intervention type: DRUG
Intervention: Pharmacological Intervention
Description: This study will include those anticipating or receiving any pharmacological intervention

Intervention type: DRUG
Intervention: Pharmacological Intervention
Description: This study will include those anticipating or receiving any pharmacological intervention
Study: NCT02441218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: 2.5mg, 5mg or 7.5mg tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 42 months.
Study: NCT03302793

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS will be applied for 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS will be applied for 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS sham

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS sham
Study: NCT04593940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: study drug or matching placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: study drug or matching placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remdesivir
Description: Standard of Care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remdesivir
Description: Standard of Care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remdesivir
Description: Standard of Care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cenicriviroc (closed to enrollment as of 3-Sep-2021)
Description: study drug or matching placebo
Study: NCT02441218

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 42 months.
Study: NCT01297855

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colistin
Description: Colistimethate Sodium dose 2.5-5mg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistin plus Rifampicin
Description: Colistin 2.5 to 5 mg/ Kg/ day Rifampin 10 mg/ Kg/ day
Study: NCT03537339

Intervention type: OTHER
Intervention: Record general information
Description: Record general information of patients' sex, age, previous history, family history, electrocardiogram, echocardiography, cardiac biomarkers TnT, BNP, biochemical examination, and clinical treatment of the patients
Study: NCT03047863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repair Control EGF®
Description: A Split face study was done. Patients applied 1 finger tip unit of EGF cream on one side of face, twice a day for 4 weeks.~EGF cream(Repair Control EGF®) containing 10 ppm of rhEGF was prepared at D.N. Co., Ltd. (Seoul, South Korea)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cream without rhEGF
Description: A Split face study was done. Patients applied 1 finger tip unit of cream on the other side of face, twice a day for 4 weeks.~Placebo cream was prepared at at D.N. Co., Ltd. (Seoul, South Korea), consisted of same ingredient with EGF cream except rhEGF
Study: NCT03648281

Intervention type: DRUG
Intervention: Semaglutide
Description: Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
Study: NCT04158713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intermittent Preventive Therapy with Dihydroartemisinin-Piperaquine
Description: Monthly DP fixed dose of 3 tablets (40 mg of dihydroartemisinin and 320 mg of piperaquine) daily for three days until delivery. All participants will (continue to) receive daily cotrimoxazole (CTX) (one double-strength tablet of 160mg of sulfamethoxazole and 800mg of trimethoprim) and anti-retroviral drugs.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intermittent Preventive Therapy with Dihydroartemisinin-Piperaquine
Description: Monthly DP fixed dose of 3 tablets (40 mg of dihydroartemisinin and 320 mg of piperaquine) daily for three days until delivery. All participants will (continue to) receive daily cotrimoxazole (CTX) (one double-strength tablet of 160mg of sulfamethoxazole and 800mg of trimethoprim) and anti-retroviral drugs.
Study: NCT03754569

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peritoneal biopsies after complete macroscopic cytoreduction
Description: We will perform at the end of complete macroscopic cytoreductive surgery (CC-0) for epithelial ovarian cancer random peritoneal biopsies in apparently healthy peritoneum in order to assess the presence of microscopic peritoneal metastases
Study: NCT06253286

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: clear aligner treatment for orthodontics patients
Description: patient are instructed to wear aligners

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: clear aligner treatment for orthodontics patients
Description: patient are instructed to wear aligners
Study: NCT01507584

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SENSIMED Triggerfish
Description: Comparison of fluctuation of Intraocular pressures with different class of drugs

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SENSIMED Triggerfish
Description: Comparison of fluctuation of Intraocular pressures with different class of drugs
Study: NCT02600325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir/Elbasvir 100mg/50mg
Description: Grazoprevir/Elbasvir 100mg/50mg
Study: NCT01426425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Freezor Xtra Cryoablation Catheter
Description: Freezor® Xtra Cardiac CryoAblation applied for cryoablation of the conducting tissues of the heart in the treatment of patients with atrioventricular nodal reentrant tachycardia using an endocardial approach.
Study: NCT01264250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2927
Description: Single dose of AZD2927

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo
Study: NCT01754220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Montelukast is a leukotriene receptor antagonist
Study: NCT02023164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JDP-205 Injection
Description: Cetirizine, 10mg/mL; a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: Diphenhydramine Injection, 50 mg/mL; a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes
Study: NCT02653976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-02L (darinaparsin for injection)
Description: Darinaparsin 300 mg/m2 once daily for 5 consecutive days every 21 days
Study: NCT01004965

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Study: NCT04801836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estetrol monohydrate 15 mg
Description: One Estetrol monohydrate (E4) 15 mg tablet once per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo tablet once per day
Study: NCT03958500

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indocyanine green fluorescent angiography intraluminally and intraperitoneally
Description: The use of indocyanine green fluorescent angiography to check bowel and anastomosis viability in standard low anterior rectal anastomosis
Study: NCT02511197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NOTA-PRGD2
Description: 68Ga-NOTA-PRGD2 were injected into the patients before the PET/CT scans

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Study: NCT04430049

Intervention type: PROCEDURE
Intervention: Covid ICU containment measures
Description: The french containment measures during Covid-19 pandemic result in a restrictive visitation for relatives in ICU

Intervention type: PROCEDURE
Intervention: Covid ICU containment measures
Description: The french containment measures during Covid-19 pandemic result in a restrictive visitation for relatives in ICU

Intervention type: PROCEDURE
Intervention: Covid ICU containment measures
Description: The french containment measures during Covid-19 pandemic result in a restrictive visitation for relatives in ICU
Study: NCT00521092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative study
Study: NCT01198340

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PC-FNB with basal administration of local anesthetics
Description: Administration of 0.2% ropivacaine for femoral nerve block with 3 ml/h of basal dose, 5ml bolus by the patient, 60 minutes of lock out time.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PC-FNB without basal local anesthetics
Description: Administration of 0.2% ropivacaine for femoral nerve block without basal dose, with 8 ml bolus by the patient, 60 minutes of lockout time.
Study: NCT02939378

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: Ketogenic diet adjuvant to salvage chemotherapy is given to recurrent glioblastomas.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Standard diet
Description: Standard diet adjuvant to salvage chemotherapy is given to recurrent glioblastomas.
Study: NCT04184804

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: The intervention package will be consisted of:~1. Introduction of organic fruits and vegetables (by replacing the conventional ones) in school lunch menus~2. Signs in school areas about organic fruits and vegetables~3. Workshops and interactive games for children~4. Seminars for parents
Study: NCT04301986

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytosponge
Description: In a seated position, subjects will swallow the Cytosponge capsule with 150-250 mL of water. Seven minutes and 30 seconds to ten minutes after ingestion, the sponge is then withdrawn by gentle traction on the suture. After retrieval, the string is cut and the retrieved foam sphere containing the cytological specimen is immersed in fixative and stored refrigerated (1° to 12°C \[34° to 54°F\]).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transnasal Endoscopy (TNE)
Description: In an upright position, the scope will be inserted via the nares to examine the posterior pharynx, esophagus and proximal stomach with the transnasal endoscopy approach. The scope will be withdrawn from the nares following completion of the exam.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transnasal Endoscopy (TNE)
Description: In an upright position, the scope will be inserted via the nares to examine the posterior pharynx, esophagus and proximal stomach with the transnasal endoscopy approach. The scope will be withdrawn from the nares following completion of the exam.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophagogastroduodenoscopy
Description: Laying on the subjects' left side, the flexible endoscope is inserted through the mouth to allow visualization of the esophageal mucosa from the upper esophageal sphincter all the way to the esophagogastric junction (EGJ).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophagogastroduodenoscopy
Description: Laying on the subjects' left side, the flexible endoscope is inserted through the mouth to allow visualization of the esophageal mucosa from the upper esophageal sphincter all the way to the esophagogastric junction (EGJ).
Study: NCT03731936

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT01630564

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Undergo ex-vivo-expanded umbilical cord blood progenitor cell donor T-cell infusion with aldesleukin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion
Description: Undergo ex-vivo-expanded umbilical cord blood progenitor cell donor T-cell infusion with aldesleukin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood-Derived Lymphocyte Therapy
Description: Undergo ex-vivo-expanded umbilical cord blood progenitor cell donor T-cell infusion with aldesleukin